Virtual Library
Start Your Search
J. Philip Boudreaux
Author of
-
+
P2.12 - Small Cell Lung Cancer/NET (Not CME Accredited Session) (ID 961)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
-
+
P2.12-07 - Utility of Stereotactic Body Radiotherapy in Pulmonary Carcinoid Tumors (ID 14162)
16:45 - 18:00 | Author(s): J. Philip Boudreaux
- Abstract
Background
Pulmonary carcinoid (PC) tumors are rare malignant neoplasms, accounting for approximately 2% of all lung cancers. While most patients with PC undergo surgical resection, some patients either decline surgery or are not surgical candidates. Stereotactic body radiotherapy (SBRT) is primarily used in patients with early stage, inoperable non-small cell lung cancer or patients who refuse surgery. We sought to determine the role of SBRT in patients with PC.
a9ded1e5ce5d75814730bb4caaf49419 Method
The records of all patients with PC seen at our clinic were retrospectively reviewed. Demographics, pathologic characteristics, and treatment data were collected. Only patients meeting the World Health Organization criteria for typical and atypical carcinoids were included. Radiographic evaluation of all patients was performed at 3-month intervals.
4c3880bb027f159e801041b1021e88e8 Result
Of the 251 patients with PC who were retrospectively reviewed, 3 patients were identified who underwent SBRT at our institution. All patients were female with a median age of 72 years. All patients received SBRT consisting of 50 Gy over 5 fractions. Median follow up time was 7 months. Median decrease in tumor size following SBRT was 29%. No adverse events from SBRT were reported.
8eea62084ca7e541d918e823422bd82e ConclusionPatient ID
1
2
3
Tumor Locality
LLL
RUL
RML
T-stage
T1b
T1b
T1b
N-stage
N0
N0
N0
M-stage
M1b
M1b
M1b
AJCC Stage Group
IV
IV
IV
Histology
Atypical
Typical
Typical
Ki-67 Index
5%
<1%
12% (liver)
Decrease in Tumor Size (cm)
0.9 (32%)
0.5 (22%)
0.7 (29%)
Duration of response (months)
7
3
5
Length of Follow up (months)
8
7
6
Our study demonstrates that SBRT is safe and feasible in patients with PC tumors. SBRT may represent a treatment option in patients with PC who are deemed inoperable due to comorbid conditions or decline surgery. Larger studies are needed to further determine the role of SBRT in PC.
6f8b794f3246b0c1e1780bb4d4d5dc53
